Cost comparison of ablation versus antiarrhythmic drugs as first-line therapy for atrial fibrillation: An economic evaluation of the RAAFT pilot study

Journal of Cardiovascular Electrophysiology

Volumn 20, Issue 1, 2009, Pages 7-12

  Khaykin, Yaariv ^a   Wang, Xiaoyin ^b   Natale, Andrea ^c   Wazni, Oussama M ^d   Skanes, Allan C ^e   Humphries, Karin H ^f   Kerr, Charles R ^f   Verma, Atul ^a   Morillo, Carlos A ^b  

^a SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c STANFORD UNIVERSITY   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f ST PAUL S HOSPITAL   (Canada)

Author keywords

Atrial fibrillation; Catheter ablation; Health economics

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; FLECAINIDE; PROPAFENONE; SOTALOL; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE TITRATION; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; MEDICAL FEE; MULTICENTER STUDY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SENSITIVITY ANALYSIS;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CANADA; CATHETER ABLATION; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MODELS, ECONOMIC; TREATMENT OUTCOME;

EID: 58149131687     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2008.01303.x     Document Type: Article

References (17)

1. Camm AJ, Obel OA : Epidemiology and mechanism of atrial fibrillation and atrial flutter. Am J Cardiol 1996 78 (8A 3 11.
2. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D : Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998 98 : 946 952.
3. Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB : Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998 158 : 229 234.
4. Connolly SJ : Preventing stroke in atrial fibrillation: Why are so many eligible patients not receiving anticoagulant therapy? CMAJ 1999 161 : 533 534.
5. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, Josephson RA, Kellen JC, Klein RC, Krahn AD, Mickel M, Mitchell LB, Nelson JD, Rosenberg Y, Schron E, Shemanski L, Waldo AL, Wyse DG : Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004 109 : 1509 1513.
6. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Metayer P, Clementy J : Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998 339 : 659 666.
7. Nademanee K, McKenzie J, Kosar E, Schwab M. Sunsaneewitayakul B, Vasavakul T, Khunnawat C, Ngarmukos T: A new approach for catheter ablation of atrial fibrillation: Mapping of the electrophysiologic substrate. J Am Coll Cardiol 2004 43 : 2044 2053.
8. Pappone C, Rosanio S, Augello G, Gallus G, Vicedomini G, Mazzone P, Gulletta S, Gugliotta F, Pappone A, Santinelli V, Tortoriello V, Sala S, Zangrillo A, Crescenzi G, Benussi S, Alfieri O : Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: Outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 2003 42 : 185 197.
9. Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, Bash D, Schweikert R, Brachmann J, Gunther J, Gutleben K, Pisano E, Potenza D, Fanelli R, Raviele A, Themistoclakis S, Rossillo A, Bonso A, Natale A : Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: A randomized trial. JAMA 2005 293 : 2634 2640.
10. Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F Jr., Bates ER, Lehmann MH, Vicedomini G, Augello G, Agricola E, Sala S, Santinelli V, Morady F : Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006 354 : 934 941.
11. Jais P, AA, Macle L, and al. e : Atrial fibrillation ablation versus antiarrhythmic drugs: A multicenter randomized trial. in Heart Rhythm Society 2006 Scientific Sessions. 2006. Boston, MA.
12. Khaykin Y, Morillo CA, Skanes AC, McCracken A, Humphries K, Kerr CR : Cost comparison of catheter ablation and medical therapy in atrial fibrillation. J Cardiovasc Electrophysiol 2007 18 : 907 913.
13. Mittmann N, Oh PI, Walker SE, Bartle WR : Warfarin in the secondary prevention of thromboembolism in atrial fibrillation: Impact of bioavailability on costs and outcomes. Pharmacoeconomics 2004 22 : 671 683.
14. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ : Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001 285 : 2864 2870.
15. Ontario Drug Benefit Formulary. 2004 cited; Available at : http://www.health.gov.on.ca/english/providers/program/drugs/odbf_eformulary. html.
16. Noorani HZ, Yee R, Marshall D, Connolly S, Nichol G, O'Brien B : Radiofrequency catheter ablation for cardiac arrhythmias: A clinical and economic review, in Canadian Coordinating Office for Health Technology Assessment. 2002, Canadian Coordinating Office for Health Technology Assessment.
17. Health Costing in Alberta 2003 Annual Report.